DiaMedica Therapeutics Announces Final Closing of Private Placement
29 mars 2018 18h08 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the second...
DiaMedica Therapeutics Announces Closing of Private Placement
20 mars 2018 17h40 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 20, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the first closing of a...
DiaMedica Announces First Enrollment in its PHASE 2 “REMEDY” TRIAL for Acute Ischemic Stroke
22 févr. 2018 07h00 HE
|
DiaMedica Therapeutics Inc.
DM199 may offer an effective and safe treatment with a significantly longer treatment window (24 hours) compared to the current standard of careREMEDY trial lead by prominent neurologist Dr. Bruce...
DiaMedica to Present at the 14th Annual Noble Investor Conference
29 janv. 2018 08h45 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSXV:DMA) (OTCQB:DMCAF), today announced that Mr. Rick Pauls, its President and CEO, will present at Noble Capital...